What are analysts'target prices for AST spacemobile's stock?
2 Wall Street analysts have issued 1-year target prices for AST SpaceMobile's shares. Their forecasts range from $29.00 to $35.00. On average, they expect AST SpaceMobile's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 329.0% from the stock's current price.
Where can I buy AST shares?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Why choose AST for your next corporate action?
Whether it’s a private company issuing its first IPO, or an established corporation handling an M&A event, restructuring, or class action litigation, successful corporate actions require dedicated operational support. For these matters, AST offers an integrated suite of services designed to help legal teams move their clients forward.
What are analysts'target prices for Asterias Biotherapeutics'stock?
1 brokers have issued 1 year target prices for Asterias Biotherapeutics' stock. Their predictions range from $11.00 to $11.00. On average, they expect Asterias Biotherapeutics' stock price to reach $11.00 in the next twelve months.
Is Ast a good stock to buy?
Is Ast Spacemobile Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: ASTS) stock is to Strong Buy ASTS stock.
Is ASTS a buy or sell?
Today ASTS ranks #14413 as sell candidate.
Is AST publicly traded?
Shareholders in AST SpaceMobile (NASDAQ:ASTS) are in the red if they invested a year ago. Investing in stocks comes with the risk that the share price will fall. Anyone who held AST SpaceMobile, Inc...
How many shares of ASTS are there?
Share StatisticsAvg Vol (3 month) 3829.25kShares Outstanding 551.9MImplied Shares Outstanding 6129.8MFloat 847.44M% Held by Insiders 121.16%7 more rows
Will ASTS go up?
AST SpaceMobile Inc (NASDAQ:ASTS) The 2 analysts offering 12-month price forecasts for AST SpaceMobile Inc have a median target of 30.00, with a high estimate of 31.00 and a low estimate of 29.00. The median estimate represents a +382.32% increase from the last price of 6.22.
What does AST SpaceMobile Inc do?
Called SpaceMobile, this ultra-powerful network is being designed to provide connectivity at 4G/5G speeds everywhere on the planet – on land, at sea and in flight. For the first time ever, mobile subscribers will be able to automatically roam from land networks to a space network.
Is AST SpaceMobile a buy?
AST SpaceMobile has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Who owns AST?
American Stock Transfer & Trust was bought out by Pacific Equity Partners for $1B on May 30, 2008 .
Who invested in ASTS?
Apex Site Management and Vodafone are the most recent investors. AST SpaceMobile has acquired 2 organizations. Their most recent acquisition was New Providence Acquisition on Dec 16, 2020 .
What is the meaning of ASTS?
ASTS. Automated Status and Tracking System.
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reporte...
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the following people: Mr. Michael H. Mulroy , CEO, Pres & Director (Age 53) Dr. Edward D. Wir...
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include Bioventix (BVXP) , Fennec Pharmaceuticals (FRX) , Agronomics (ANIC) , Redx...
What other stocks do shareholders of Asterias Biotherapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Brooklyn Im...
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull...
How much money does Asterias Biotherapeutics make?
Asterias Biotherapeutics (NYSEAMERICAN:AST) has a market capitalization of $0.00.
What is Asterias Biotherapeutics' official website?
The official website for Asterias Biotherapeutics is asteriasbiotherapeutics.com .
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States . The biotechnology company can be reached...
0.0 Analyst's Opinion
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics has received 139 “outperform” votes. (Add your “outperform” vote.)
Who are some of Asterias Biotherapeutics' key competitors?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) posted its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01.
What other stocks do shareholders of Asterias Biotherapeutics own?
Some companies that are related to Asterias Biotherapeutics include Resverlogix (RVX), Ampliphi Biosciences (APHB), Agronomics (ANIC), BriaCell Therapeutics (BCT), Bioventix (BVXP), Arix Bioscience (ARIX), Fennec Pharmaceuticals (FRX), Circassia Group (CIR), e-therapeutics (ETX), Faron Pharmaceuticals Oy (FARN), Aptose Biosciences (APS), Burcon NutraScience (BU), Novacyt (NCYT), ImmunoPrecise Antibodies (IPA) and IMV (IMV). View all of AST's competitors..
What is Asterias Biotherapeutics' stock symbol?
Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Brooklyn ImmunoTherapeutics (BTX), Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), CorMedix (CRMD), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), (XXII), Amarin (AMRN), Anavex Life Sciences (AVXL) and Freeport-McMoRan (FCX)..
How do I buy shares of Asterias Biotherapeutics?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
What is Asterias Biotherapeutics' stock price today?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Shareholders in AST SpaceMobile (NASDAQ:ASTS) are in the red if they invested a year ago
One share of AST stock can currently be purchased for approximately $0.94.
Here's Why We're Not Too Worried About AST SpaceMobile's (NASDAQ:ASTS) Cash Burn Situation
Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of AST SpaceMobile, Inc...
AST SpaceMobile Provides Update on BlueWalker 3 Launch Timing
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Who We Are
MIDLAND, Texas, December 06, 2021--AST SpaceMobile, Inc., provides updated timing for the launch of its next satellite, BlueWalker 3.
What We Offer
AST is a tech-enabled, integrated, professional services firm that empowers companies and their stakeholders to achieve their goals through advisory, technology and flawless execution.
Solutions by Function
We are your strategic partner for positive shareholder engagement, transfer agent excellence, control of essential ownership records, and employee plans.
In the News
Lorem ipsum dolor sit amet, con setetur sa di pscing elitr sed diam non umy eirmod tempo in vidunt ut la bore et dolore magna ali quyam erat, sed diam vol sed diam uptua at vero eos et accusam et justo non umy eirmod temp invidunduo et.
Insights
Comprehensive guide provides data, charts and commentary on key topics including: Top Shareholder Proposals, Say-on-Pay & Equity Plans, COVID-19 and Its Lingering Effects on the Proxy Season, and Trends in Shareholder Engagement and Investor Behavior.
